Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

Background Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD)
patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes …

Ulcerative colitis is a common chronic inflammatory disease of the colon and rectum,
resulting from a dysregulated immune response towards intraluminal antigens in a …

Abstract The Asia–Pacific Working Group on Inflammatory Bowel Disease was established
in Cebu, Philippines, under the auspices of the Asia–Pacific Association of Gastroenterology …

Summary The coronavirus disease 2019 (COVID-19) pandemic is changing the
management of many chronic diseases, including that of patients with inflammatory bowel …

Background Medication persistence contributes real‐world evidence about treatment
effectiveness, tolerability and prescriber and patient acceptability. Aims To evaluate …

Background One-third of patients with acute severe ulcerative colitis [ASUC] are steroid-
refractory. We aimed to review the different options for the management of steroid-refractory …

Background Infliximab is an effective salvage therapy in acute severe ulcerative colitis;
however, the optimal dosing strategy is unknown. We performed a systematic review and …

Background Although optimal medical management of acute severe ulcerative colitis (UC) is
ill‐defined, infliximab has become a standard of care. Accumulating evidence suggests an …

Ulcerative colitis (UC) is a chronic inflammatory bowel disease of the colorectum which
results from a complex interplay between environmental, genetic and microbial factors. One …